KR980000445A - 인식 증강 방법 - Google Patents

인식 증강 방법 Download PDF

Info

Publication number
KR980000445A
KR980000445A KR1019970025073A KR19970025073A KR980000445A KR 980000445 A KR980000445 A KR 980000445A KR 1019970025073 A KR1019970025073 A KR 1019970025073A KR 19970025073 A KR19970025073 A KR 19970025073A KR 980000445 A KR980000445 A KR 980000445A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
treatment
acetylcholinesterase inhibitor
darfenacin
Prior art date
Application number
KR1019970025073A
Other languages
English (en)
Inventor
마이클 존 알렌
브리안 프랑크 존슨
브리안 로버트 리커
로버트 마이클 왈리스
Original Assignee
무어 제임스 더블유
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 무어 제임스 더블유, 화이자 인코포레이티드 filed Critical 무어 제임스 더블유
Publication of KR980000445A publication Critical patent/KR980000445A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Eletrric Generators (AREA)
  • Soil Working Implements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

다리페나신 및 그의 약학적으로 허용가능한 염은 인식 장애의 치료에 유용하다.
본 발명은 또한 다리페나신 또는 그의 약학적으로 허용가능한 염과 아세틸콜린에스터레이즈 억제제와의 혼합된 제제의 인식 장애의 치료에서의 용도를 개시한다.

Description

인식 증강 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 다리페나신 또는 그의 약학적으로 허용가능한 염, 및 약학적으로 허용가능한 아쥬방트, 회석제 또는 담체를 포함하는 인식 장애 치료용 약제.
  2. 제1항에 있어서, 아세틸콜린에스터레이즈 억제제를 더욱 포함하는 약제.
  3. 제2항에 있어서, 아세틸콜린에스터레이즈 억제제가 도네피질 또는 그의 약학적으로 허용가능한 염인 약제.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 인식 장애가 알쯔하이며 병에 기인한 약제.
  5. 제1항 내지 제3항 중 어느 한 항에 있어서, 인식 장애가 노령과 연관된 기억 장애에 기인한 약제.
  6. 인식 장애의 치료시 동시에, 개별적으로 또는 순차적으로 사용되는 혼합된 제제로서 다리페나신 또는 그의 약학적으로 허용가능한 염 및 아세틸콜린에스터레이즈 억제제를 함유하는 약품.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970025073A 1996-06-18 1997-06-17 인식 증강 방법 KR980000445A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9612710.5 1996-06-18
GBGB9612710.5A GB9612710D0 (en) 1996-06-18 1996-06-18 Method of treatment

Publications (1)

Publication Number Publication Date
KR980000445A true KR980000445A (ko) 1998-03-30

Family

ID=10795468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970025073A KR980000445A (ko) 1996-06-18 1997-06-17 인식 증강 방법

Country Status (15)

Country Link
US (1) US5837724A (ko)
EP (1) EP0813870B1 (ko)
JP (1) JP3453493B2 (ko)
KR (1) KR980000445A (ko)
AT (1) ATE243514T1 (ko)
AU (1) AU2495697A (ko)
CA (1) CA2208111C (ko)
DE (1) DE69722999T2 (ko)
DK (1) DK0813870T3 (ko)
ES (1) ES2197972T3 (ko)
GB (1) GB9612710D0 (ko)
HU (1) HUP9701060A3 (ko)
IL (1) IL121036A0 (ko)
PT (1) PT813870E (ko)
ZA (1) ZA975311B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
WO2004089892A2 (en) * 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
ES2634421T3 (es) 2008-03-27 2017-09-27 Chase Pharmaceuticals Corporation Uso y composición para tratar la demencia
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (hu) * 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
KR102627787B1 (ko) * 2017-06-01 2024-01-23 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체와 도네페질을 병용한 치매 치료제
SG11202102349PA (en) 2018-09-28 2021-04-29 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
HUP9701060A2 (hu) 1998-12-28
PT813870E (pt) 2003-10-31
ES2197972T3 (es) 2004-01-16
JPH1059848A (ja) 1998-03-03
HU9701060D0 (en) 1997-08-28
HUP9701060A3 (en) 1999-03-29
EP0813870B1 (en) 2003-06-25
DE69722999T2 (de) 2003-12-18
US5837724A (en) 1998-11-17
CA2208111C (en) 2002-10-15
DE69722999D1 (de) 2003-07-31
ATE243514T1 (de) 2003-07-15
DK0813870T3 (da) 2003-08-18
CA2208111A1 (en) 1997-12-18
IL121036A0 (en) 1997-11-20
EP0813870A1 (en) 1997-12-29
AU2495697A (en) 1998-01-08
ZA975311B (en) 1998-12-17
GB9612710D0 (en) 1996-08-21
JP3453493B2 (ja) 2003-10-06

Similar Documents

Publication Publication Date Title
FI961809A (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
KR930012022A (ko) 뇌조직 보호용 모다피닐(Modafinil)
DK0562512T3 (da) Sulfonamidocarbonylpyridin-2-carboxylsyreamider samt deres anvendelse som lægemidler
FI903153A0 (fi) 11b-aryl-4-estrener, foerfarande foer deras framstaellning samt deras anvaendning som laekemedel.
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
DK0422485T3 (da) Quinoloncarboxylsyrederivater, fremgangsmåder til deres fremstilling samt deres anvendelse som antivirale midler
KR980000445A (ko) 인식 증강 방법
ATE56956T1 (de) (s)-(-)-1-propyl-2',6'-pipecoloxylididhydrochloridmonohydrat, verfahren zu seiner herstellung und es enthaltendes pharmazeutisches praeparat.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
HUT50325A (en) Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
KR930023338A (ko) 데포우 제제
DE69623641T2 (de) Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen
FR2722689B1 (fr) Nouveau produit de combinaison comprenant un agent antifongique et du crotamiton comme potentialisateur de l'activite de l'agent antifongique, et compositions dermatologiques et/ou cosmetiques le comprenant
NO975790L (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
MXPA05009763A (es) 2-(butil-1-sulfonilamino)-n-[1 (r)-(6-metoxipiridin-3-il) propil] benzamida, su uso en forma de un farmaco y preparaciones farmaceuticas que contienen a dicho compuesto.
RU94036762A (ru) Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
BR9607841A (pt) Método para a preparação de estéres de anidroeggonina
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application